Navigation Links
Interviewed Payers in the EU5 Anticipate Increasing Prescribing Constraints for Premium-Priced Type 2 Diabetes Agents
Date:9/15/2014

BURLINGTON, Mass., Sept. 15, 2014 /PRNewswire/ -- Decision Resources Group finds that as the type 2 diabetes treatment armamentarium continues to expand, increasing pressure to control expenditures will result in mounting prescribing constraints for premium-priced agents. Interviewed payers emphasize that although type 2 diabetes drugs will generally be reimbursable at the national level, regional formularies are likely to enforce additional restrictions on expensive agents. Surveyed physicians in most EU5 countries (France, Germany, Italy, Spain and the United Kingdom) agree that patient access to premium-priced type 2 diabetes therapies is at least somewhat restricted by regional or hospital formulary variation, and most physicians expect this situation to deteriorate by the end of 2016.

Other key findings from the European Physician & Payer Forum report entitled The Dynamic Type 2 Diabetes Landscape: Market Access Levers and Barriers amid Increasing Austerity in the EU5:

  • Pricing and reimbursement conditions: Payers emphasize that demonstration of benefit in specific subgroups as well as the potential for downstream cost savings will be key to optimizing pricing and reimbursement conditions.
  • Enforced prescribing: Surveyed physicians identify promotion of generic agents as the most common strategy for managing drug costs and, like payers, anticipate that use of biosimilar insulin will be encouraged when it becomes available.
  • Future uptake of branded type 2 diabetes therapies: Despite mounting pressure to control expenditures, physicians report increasing use of the DPP-IV inhibitor and GLP-1 receptor agonist classes over the last 12 months, and anticipate robust uptake of the relatively new SGLT-2 inhibitor class as well as the novel GLP-1 receptor agonist/insulin analogue fixed-dose combinations over the next two years.

Comments from Decision Resources Group Analyst Dr. Eamonn O'Connor, Ph.D.:

  • "Accepting prescribing restrictions may expedite market entry, and the pricing and reimbursement negotiations for AstraZeneca's Forxiga in Spain is a good example of this. Spanish payers report that negotiation of an inspection visa for Forxiga helped accelerate this agent's market entry in Spain, where national negotiations are typically lengthy relative to other European markets."
  • "Proven benefit in specific subgroups and clear demonstration of potential for downstream cost savings will encourage payers to see beyond the price tag. In particular, payers are looking for novel agents that delay disease progression and demonstrate weight-loss efficacy and positive cardiovascular outcomes data."

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>
SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. GSK CEO and CFO Interviewed on Q2 2014 Results and Strategy Update
2. GlaxoSmithKline CFO Interviewed on Q3 results
3. GlaxoSmithKline CFO Interviewed on Q2 Results
4. GlaxoSmithKline CFO Interviewed on Q1 2013 Financial Results
5. GSK CEO Sir Andrew Witty Interviewed on Q2 2012 Results
6. Despite Increasing Cost Sensitivity of EU5 Payers, Sofosbuvir and Simeprevir are Poised to Reshape the Hepatitis C Virus Market by End of 2015
7. Express Scripts Launches Workers Compensation Program To Help Payers Reduce Narcotic Abuse
8. Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idecs Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
9. Express Scripts Research Shows Prescription Drug Utilization Declines for Payers of Workers Compensation
10. Elseviers MEDalternatives Offers Additional Cost Saving Options for Payers and Members
11. iPads Transforming How Pharma Sales Forces Interact with Physicians & Payers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2020)... NEW YORK (PRWEB) , ... July 01, 2020 , ... ... showed that University Hospitals Ahuja Medical Center , Southwest General Health Center ... a 90 day episode for Hip & Knee replacement. Dexur’s value analysis tracks a ...
(Date:6/28/2020)... ... June 26, 2020 , ... Mediaplanet is ... brings together patients, healthcare providers, advocates, and scientists to spread awareness of chronic ... these devastating respiratory conditions. , More than 35 million Americans live ...
(Date:6/25/2020)... ... June 25, 2020 , ... ... unmet needs in the field of urology, today announced that Tarek Pacha, D.O., ... Excellence. The designation recognizes that Dr. Pacha has achieved a high level of ...
Breaking Medicine Technology:
(Date:7/2/2020)... Conn. (PRWEB) , ... July 02, 2020 , ... ... of many businesses, including dental offices for non-emergency work. In conjunction with the ... reopening guidelines for Connecticut dental practices in mid-May. , Due to safety ...
(Date:7/1/2020)... TAMPA, Fla. (PRWEB) , ... July 01, 2020 ... ... biotechnology LLC specializing in the clinical development of psychedelics and analogues, announces its ... years combined experience in natural product drug discovery, novel formulations, and as distinguished ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... in the revision and redesignation of the ANSI/APSP/ICC-7 2013 American National Standard for ... Basins. PHTA is seeking member participation on the PHTA-7 Standard Writing Committee (SWC) ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... Inland Empire’s premier residential addiction treatment center, proudly announces that it has reopened ... special preparation for recovery in a world affected by Covid-19. , When social-distancing ...
(Date:6/28/2020)... LEXINGTON, Mass. (PRWEB) , ... June 27, 2020 ... ... its FSHD Connect Classroom, the first online, full-day educational conference in the organization’s ... educational meeting for facioscapulohumeral muscular dystrophy (FSHD), which was cancelled this year due ...
Breaking Medicine News(10 mins):